Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors

Background: The presented phase I, first-in-human study evaluated the tolerance, pharmacokinetics, and preliminary efficacy of larotinib mesylate in patients with advanced solid tumors. Methods: Cancer patients were assigned to receive larotinib mesylate at 50–400 mg dose levels until disease progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jingrui, Zhang, Hong, Zhu, Xiaoxue, Chen, Hong, Li, Xiaojiao, Ding, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930822/
https://www.ncbi.nlm.nih.gov/pubmed/33679419
http://dx.doi.org/10.3389/fphar.2021.636324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930822/
https://www.ncbi.nlm.nih.gov/pubmed/33679419
http://dx.doi.org/10.3389/fphar.2021.636324

Ejemplares similares